The single institutional outcome of postoperative radiotherapy and concurrent chemoradiotherapy in resected non-small cell lung cancer.
10.3857/roj.2014.32.3.147
- Author:
Hyo Chun LEE
1
;
Yeon Sil KIM
;
Se Jin OH
;
Yun Hee LEE
;
Dong Soo LEE
;
Jin Ho SONG
;
Jin Hyung KANG
;
Jae Kil PARK
Author Information
1. Department of Radiation Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea. yeonkim7@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Non-small-cell lung carcinoma;
Radiotherapy;
Chemoradiotherapy
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Chemoradiotherapy*;
Disease-Free Survival;
Drug Therapy;
Humans;
Multivariate Analysis;
Radiation Pneumonitis;
Radiotherapy*;
Treatment Failure
- From:Radiation Oncology Journal
2014;32(3):147-155
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study was conducted to observe the outcomes of postoperative radiotherapy (PORT) with or without concurrent chemotherapy in resected non-small cell lung cancer (NSCLC) in single institution. MATERIALS AND METHODS: From 2002 to 2013, 78 patients diagnosed with NSCLC after curative resection were treated with radiotherapy alone (RT, n = 48) or concurrent chemoradiation (CCRT, n = 30). The indications of adjuvant radiation therapy were N2 node positive (n = 31), close or involved resection margin (n = 28), or gross residual disease due to incomplete resection (n = 19). The median radiation dose was 57.6 Gy (range, 29.9 to 66 Gy). RESULTS: Median survival time was 33.7 months (range, 4.4 to 140.3 months). The 5-year overall survival (OS) rate was 49.5% (RT 46% vs. CCRT 55.2%; p = 0.731). The 3-year disease-free survival rate was 45.5% (RT 39.4% vs. CCRT 55.3%; p = 0.130). The 3-year local control rate was 68.1% (RT 64.4% vs. CCRT 77.7%; p = 0.165). The 3-year DMFS rate was 56.1% (RT 52.6% vs. CCRT 61.7%; p = 0.314). In multivariate analysis, age > or =66 years and pathologic stage III were significant poor prognostic factors for OS. Treatment failure occurred in 40 patients. Four patients had radiologically confirmed grade 3 radiation pneumonitis. CONCLUSION: In NSCLC, adjuvant RT or CCRT after curative surgery is a safe and feasible modality of treatment. OS gain was seen in patients less than 66 years. Postoperative CCRT showed a propensity of achieving better local control and improved disease-free survival compared to RT alone according to our data.
